了解患者症状与提供者在IBD中的粘膜治疗目标之间的联系:IBD Qorus调查的见解
Angela Troia1, Sarah Harvey2, Angela Wu3
1Department of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Building 2, Washington, DC, 20007, USA. Angela.Troia@medstar.net.
在炎症性肠病 (IBD) 中,症状严重程度影响但不能完全决定治疗决定的粘膜愈合. 临床医生在规划IBD患者的测试和治疗变化时考虑症状.
科学领域:
- 胃肠病学和肝病学 胃肠学和肝病学
- 临床研究 临床研究
- 患者的治疗结果.
背景情况:
- 症状严重程度传统上指导炎症性肠病 (IBD) 治疗,但症状可能不准确地反映肠道炎症.
- 粘膜愈合是IBD的关键治疗目标,因为它与更好的长期结果有关.
- 症状严重程度对在临床实践中追求粘膜愈合的影响仍然不清楚.
研究的目的:
- 研究患者报告的症状严重程度如何影响临床医生的诊断测试和IBD粘膜愈合治疗调整的决定.
- 分析特定IBD症状与内镜或生物标志物检测的可能性之间的关系.
主要方法:
- 来自IBD Qorus质量改进计划 (2021年6月至2022年10月) 的5460个匹配患者和提供者调查的分析.
- 评估患者报告的症状 (便频率,直肠出血,腹痛,健康状况) 与提供者对内镜,便calprotectin测试和治疗变化的计划进行对比.
主要成果:
- 提供者计划在一年内对超过60%的临床缓解期患者进行内镜或生物标志物测试.
- 症状严重程度增加 (便频率,直肠出血,健康状况不佳) 与较早的测试和治疗调整相关.
- 腹部疼痛与测试决策没有显著关联;提供者注意到便calprotectin测试时间的不确定性,特别是对于克罗恩病.
结论:
- 提供者决定评估或治疗IBD的粘膜愈合与症状严重程度有关,但不仅仅由此驱动.
- 症状严重程度起着作用,但其他因素可能会影响在IBD管理中追求粘膜愈合.
更多相关视频
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
08:52Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
Published on: February 5, 2021
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Irritable Bowel Syndrome III: Medical and Nursing Management
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
